Midomafetamine

Generic Name: Midomafetamine

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₅NO_₂

CAS Number: 42542-10-9

Unique Ingredient Identifier: KE1SEN21RM

Background: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

Indication: Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.

Clinical Trials

MDMA-assisted Therapy for Fibromyalgia

Early Phase 1

Not yet recruiting

Conditions: Fibromyalgia

First Posted Date: 2023-10-04

Last Posted Date: 2024-04-12

Lead Sponsor: Spaulding Rehabilitation Hospital

Target Recruit Count: 20

Registration Number: NCT06066853

Locations: 🇺🇸
Massachusetts General Hospital, Charlestown, Massachusetts, United States

MDMA-Assisted CBCT for PTSD vs CBCT RCT

Phase 2

Recruiting

Conditions: Post Traumatic Stress Disorder

Interventions: Behavioral: Psychotherapy
Drug: MDMA assisted psychotherapy

First Posted Date: 2023-09-21

Last Posted Date: 2024-11-26

Lead Sponsor: Remedy

Target Recruit Count: 60

Registration Number: NCT06044675

Locations: 🇨🇦
Remedy Institute, Toronto, Ontario, Canada

MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD

Phase 3

Active, not recruiting

Conditions: PTSD
Relational Problems

Interventions: Drug: 3,4-methylenedioxymethamphetamine (MDMA)
Behavioral: Brief Cognitive Behavioral Conjoint Therapy (bCBCT)

First Posted Date: 2023-08-07

Last Posted Date: 2025-04-16

Lead Sponsor: Dr. Leslie Morland

Target Recruit Count: 16

Registration Number: NCT05979844

Locations: 🇺🇸
VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States

Group MDMA-therapy for Veterans With PTSD

Phase 1

Active, not recruiting

Conditions: PTSD

Interventions: Drug: MDMA
Behavioral: Group Therapy

First Posted Date: 2023-07-27

Last Posted Date: 2024-08-21

Lead Sponsor: Portland VA Research Foundation, Inc

Target Recruit Count: 23

Registration Number: NCT05961527

Locations: 🇺🇸
Portland-Vancouver VA, Vancouver, Washington, United States

Prosocial Effects of MDMA

Early Phase 1

Completed

Conditions: MDMA ('Ecstasy')
Social Interaction

Interventions: Drug: MDMA
Drug: Placebo

First Posted Date: 2023-07-17

Last Posted Date: 2024-08-19

Lead Sponsor: University of Chicago

Target Recruit Count: 33

Registration Number: NCT05948683

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

MDMA for AUD/PTSD Comorbidity

Phase 2

Recruiting

Conditions: Alcohol Use Disorder
Post Traumatic Stress Disorder

Interventions: Drug: MDMA

First Posted Date: 2023-07-13

Last Posted Date: 2025-02-10

Lead Sponsor: Carolina L Haass-Koffler

Target Recruit Count: 18

Registration Number: NCT05943665

Locations: 🇺🇸
Brown University, Providence, Rhode Island, United States

MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans with Severe Posttraumatic Stress Disorder

Phase 2

Recruiting

Conditions: PTSD

Interventions: Drug: MDMA
Behavioral: Cognitive Processing Therapy
Behavioral: MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT)

First Posted Date: 2023-05-01

Last Posted Date: 2025-02-17

Lead Sponsor: Patricia Suppes

Target Recruit Count: 30

Registration Number: NCT05837845

Locations: 🇺🇸
VA Palo Alto Health Care System / Stanford University, Palo Alto, California, United States

Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: MDMA 120 mg + MDMA 60 mg
Drug: MDMA 120 mg + placebo

First Posted Date: 2023-04-12

Last Posted Date: 2025-03-19

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 25

Registration Number: NCT05809271

Locations: 🇨🇭
University Hospital, Basel, Switzerland

MDMA-Assisted Therapy for Veterans with Moderate to Severe Post Traumatic Stress Disorder

Phase 2

Recruiting

Conditions: Post Traumatic Stress Disorder

Interventions: Drug: d-amphetamine
Drug: 3,4-methylenedioxymethamphetamine
Behavioral: Therapy

First Posted Date: 2023-03-30

Last Posted Date: 2025-03-28

Lead Sponsor: Stephen Robert Marder

Target Recruit Count: 40

Registration Number: NCT05790239

Locations: 🇺🇸
West Los Angeles Veteran Affairs, Los Angeles, California, United States
🇺🇸
VA Greater Los Angeles Healthcare System, Westwood campus, Los Angeles, California, United States

Tolerability of MDMA in Schizophrenia

Phase 1

Recruiting

Conditions: Schizophrenia

Interventions: Drug: MDMA 40mg
Drug: MDMA 80mg
Drug: MDMA 120mg

First Posted Date: 2023-03-15

Last Posted Date: 2025-05-11

Lead Sponsor: Anya Bershad, MD, PhD

Target Recruit Count: 20

Registration Number: NCT05770375

Locations: 🇺🇸
UCLA, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy